PL441261A1 - Formulacja nanocząstek fosforanu wapnia o zwiększonym wychwycie komórkowym modyfikowanych lecytyną jako nośnika bisfosfonianów oraz sposób jej wytwarzania - Google Patents

Formulacja nanocząstek fosforanu wapnia o zwiększonym wychwycie komórkowym modyfikowanych lecytyną jako nośnika bisfosfonianów oraz sposób jej wytwarzania

Info

Publication number
PL441261A1
PL441261A1 PL441261A PL44126122A PL441261A1 PL 441261 A1 PL441261 A1 PL 441261A1 PL 441261 A PL441261 A PL 441261A PL 44126122 A PL44126122 A PL 44126122A PL 441261 A1 PL441261 A1 PL 441261A1
Authority
PL
Poland
Prior art keywords
bisphosphonate
formulation
calcium phosphate
lecithin
carrier
Prior art date
Application number
PL441261A
Other languages
English (en)
Inventor
Michał Wojasiński
Jolanta CZERSKA-DUSZAK
Joanna Latocha
Artur Małolepszy
Tomasz CIACH
Original Assignee
Politechnika Warszawska
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Politechnika Warszawska filed Critical Politechnika Warszawska
Priority to PL441261A priority Critical patent/PL441261A1/pl
Priority to CN202380015229.XA priority patent/CN118541142A/zh
Priority to PCT/IB2023/055336 priority patent/WO2023228105A1/en
Priority to US18/867,537 priority patent/US20250381141A1/en
Priority to EP23738854.1A priority patent/EP4426268A1/en
Priority to JP2024545889A priority patent/JP2025517853A/ja
Publication of PL441261A1 publication Critical patent/PL441261A1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C01—INORGANIC CHEMISTRY
    • C01B—NON-METALLIC ELEMENTS; COMPOUNDS THEREOF; METALLOIDS OR COMPOUNDS THEREOF NOT COVERED BY SUBCLASS C01C
    • C01B25/00—Phosphorus; Compounds thereof
    • C01B25/01—Treating phosphate ores or other raw phosphate materials to obtain phosphorus or phosphorus compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1611—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/40—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material
    • A61L27/44—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
    • A61L27/46—Composite materials, i.e. containing one material dispersed in a matrix of the same or different material having a macromolecular matrix with phosphorus-containing inorganic fillers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/54—Biologically active materials, e.g. therapeutic substances
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
    • A61L27/00—Materials for grafts or prostheses or for coating grafts or prostheses
    • A61L27/50—Materials characterised by their function or physical properties, e.g. injectable or lubricating compositions, shape-memory materials, surface modified materials
    • A61L27/58—Materials at least partially resorbable by the body
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Oral & Maxillofacial Surgery (AREA)
  • Transplantation (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Materials Engineering (AREA)
  • Environmental & Geological Engineering (AREA)
  • General Life Sciences & Earth Sciences (AREA)
  • Geochemistry & Mineralogy (AREA)
  • Geology (AREA)
  • Composite Materials (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Przedmiotem zgłoszenia jest formulacja nanocząstek fosforanu wapnia, korzystnie hydroksyapatytu, modyfikowanych lecytyną, korzystnie fosfatydylocholiną, o zwiększonym wychwycie komórkowym jako nośnik bisfosfonianu, charakteryzująca się tym że bisfosfonian jest wybrany z grupy leków-bisfosfonianów dopuszczonych do zastosowań medycznych obejmującej alendronian oraz zoledronian, bisfosfonian jest enkapsulowany w nanocząstkach fosforanu wapnia w ilości do 40% masowych a nanocząstki mają rozmiar poniżej 200 nm. Przedmiotem zgłoszenia jest również sposób otrzymywania formulacji.
PL441261A 2022-05-24 2022-05-24 Formulacja nanocząstek fosforanu wapnia o zwiększonym wychwycie komórkowym modyfikowanych lecytyną jako nośnika bisfosfonianów oraz sposób jej wytwarzania PL441261A1 (pl)

Priority Applications (6)

Application Number Priority Date Filing Date Title
PL441261A PL441261A1 (pl) 2022-05-24 2022-05-24 Formulacja nanocząstek fosforanu wapnia o zwiększonym wychwycie komórkowym modyfikowanych lecytyną jako nośnika bisfosfonianów oraz sposób jej wytwarzania
CN202380015229.XA CN118541142A (zh) 2022-05-24 2023-05-24 作为双膦酸盐的载体的具有增强的细胞摄取的经卵磷脂改性的磷酸钙纳米颗粒的制剂及其制备方法
PCT/IB2023/055336 WO2023228105A1 (en) 2022-05-24 2023-05-24 Formulation of lecithin-modified calcium phosphate nanoparticles with an enhanced cellar uptake as a carrier for bisphosphonates and a method of preparing thereof
US18/867,537 US20250381141A1 (en) 2022-05-24 2023-05-24 Formulation of lecithin-modified calcium phosphate nanoparticles with an enhanced cellar uptake as a carrier for bisphosphonates and a method of preparing thereof
EP23738854.1A EP4426268A1 (en) 2022-05-24 2023-05-24 Formulation of lecithin-modified calcium phosphate nanoparticles with an enhanced cellar uptake as a carrier for bisphosphonates and a method of preparing thereof
JP2024545889A JP2025517853A (ja) 2022-05-24 2023-05-24 ビスホスホネートの担体としての細胞取り込みが向上したレシチン修飾リン酸カルシウムナノ粒子の製剤化とその調製方法

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL441261A PL441261A1 (pl) 2022-05-24 2022-05-24 Formulacja nanocząstek fosforanu wapnia o zwiększonym wychwycie komórkowym modyfikowanych lecytyną jako nośnika bisfosfonianów oraz sposób jej wytwarzania

Publications (1)

Publication Number Publication Date
PL441261A1 true PL441261A1 (pl) 2023-11-27

Family

ID=87158549

Family Applications (1)

Application Number Title Priority Date Filing Date
PL441261A PL441261A1 (pl) 2022-05-24 2022-05-24 Formulacja nanocząstek fosforanu wapnia o zwiększonym wychwycie komórkowym modyfikowanych lecytyną jako nośnika bisfosfonianów oraz sposób jej wytwarzania

Country Status (6)

Country Link
US (1) US20250381141A1 (pl)
EP (1) EP4426268A1 (pl)
JP (1) JP2025517853A (pl)
CN (1) CN118541142A (pl)
PL (1) PL441261A1 (pl)
WO (1) WO2023228105A1 (pl)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0606280A2 (pt) * 2005-03-17 2009-06-09 Elan Pharma Int Ltd composições de bisfosfonato nanoparticulado
IT1401882B1 (it) * 2010-10-01 2013-08-28 Rosa De Nanoparticelle autoassemblanti per il rilascio di bifosfonati nel trattamento di tumori.
CN107007552A (zh) * 2017-04-26 2017-08-04 温州医科大学附属口腔医院 一种载抗骨吸收药物纳米颗粒脂‑聚合物的制备方法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FAZIL, MOHAMMAD, ET AL.: "2015, 22.1: 1-9.", BISPHOSPHONATES: THERAPEUTICS POTENTIAL AND RECENT ADVANCES IN DRUG DELIVERY. DRUG DELIVERY, *
SAPINO, SIMONA, ET AL.: "2021, 11.11: 2983", CALCIUM PHOSPHATE-COATED LIPID NANOPARTICLES AS A POTENTIAL TOOL IN BONE DISEASES THERAPY. NANOMATERIALS, *
SUN, RUI, ET AL.: "2019, 10.1: 20", HIGHLY POROUS AMORPHOUS CALCIUM PHOSPHATE FOR DRUG DELIVERY AND BIO-MEDICAL APPLICATIONS. NANOMATERIALS, . *

Also Published As

Publication number Publication date
CN118541142A (zh) 2024-08-23
US20250381141A1 (en) 2025-12-18
JP2025517853A (ja) 2025-06-12
WO2023228105A1 (en) 2023-11-30
EP4426268A1 (en) 2024-09-11

Similar Documents

Publication Publication Date Title
Bigi et al. Calcium phosphates as delivery systems for bisphosphonates
He et al. Biomineralization of dentin
Ghosh et al. Self-setting calcium phosphate cements with tunable antibiotic release rates for advanced antimicrobial applications
Nitiputri et al. Nanoanalytical electron microscopy reveals a sequential mineralization process involving carbonate-containing amorphous precursors
Wu et al. Hyaluronic acid-mediated collagen intrafibrillar mineralization and enhancement of dentin remineralization
Pascaud et al. Adsorption on apatitic calcium phosphates for drug delivery: interaction with bisphosphonate molecules
Cuylear et al. Calcium phosphate delivery systems for regeneration and biomineralization of mineralized tissues of the craniofacial complex
Ewald et al. Effect of cold‐setting calcium‐and magnesium phosphate matrices on protein expression in osteoblastic cells
DE60300666D1 (de) Verfahren zur Herstellung poröser Calciumphosphatstückchen und -granulaten aus der Gelatineverarbeitung
Kos et al. Bisphosphonates enhance bacterial adhesion and biofilm formation on bone hydroxyapatite
MX346469B (es) Control de la textura de composiciones alimenticias altas en proteina que comprenden caseina micelar.
BR112015013539A2 (pt) composições de formação de cimento, cimentos monetita, implantes e métodos para a correção de defeitos de ossos
Duan et al. Osteocompatibility evaluation of poly (glycine ethyl ester‐co‐alanine ethyl ester) phosphazene with honeycomb‐patterned surface topography
BR0110618A (pt) Composição farmacêutica similar a gel para administraçâo subcutânea compreendendo ácidos bis-fosfÈnicos ou seus sais
Ko et al. Osteoregenerative capacities of dicalcium phosphate‐rich calcium phosphate bone cement
Pina et al. In vitro performance assessment of new brushite‐forming Zn‐and ZnSr‐substituted β‐TCP bone cements
Paul et al. In vivo evaluation of injectable calcium phosphate cement composed of Zn‐and Si‐incorporated β‐tricalcium phosphate and monocalcium phosphate monohydrate for a critical sized defect of the rabbit femoral condyle
PL441261A1 (pl) Formulacja nanocząstek fosforanu wapnia o zwiększonym wychwycie komórkowym modyfikowanych lecytyną jako nośnika bisfosfonianów oraz sposób jej wytwarzania
Gelli et al. Unravelling the effect of citrate on the features and biocompatibility of magnesium phosphate-based bone cements
Ni et al. The effect of strontium incorporation into hydroxyapatites on their physical and biological properties
Yokota et al. Quantitative Evaluation of MDP-Ca Salt and DCPD after Application of an MDP-based One-step Self-etching Adhesive on Enamel and Dentin.
EA201692454A1 (ru) Твердая фосфатная соль и способ ее получения
Medvecky et al. Enzymatically hardened calcium phosphate biocement with phytic acid addition
Mystkowska et al. Tribological properties of selected self-made solutions of synthetic saliva
BR112022004980A2 (pt) Composições de poliamida, método para fabricar um artigo e método para fazer uma composição de poliamida